Tanaka et al., 2003 - Google Patents
Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodiesTanaka et al., 2003
View PDF- Document ID
- 5609976672402554792
- Author
- Tanaka T
- Lobato M
- Rabbitts T
- Publication year
- Publication venue
- Journal of molecular biology
External Links
Snippet
There is a major need in target validation and therapeutic applications for molecules that can interfere with protein function inside cells. Intracellular antibodies (intrabodies) can bind to specific targets in cells but isolation of intrabodies is currently difficult. Intrabodies are …
- 102000004965 antibodies 0 title abstract description 66
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tanaka et al. | Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies | |
| Tse et al. | Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein | |
| CN112625136B (en) | Bispecific antibodies having neutralizing activity against coronaviruses and uses thereof | |
| Caldas et al. | Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen | |
| Aires da Silva et al. | Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs | |
| US20100143939A1 (en) | Intracellular antibodies | |
| WO2021058000A1 (en) | Anti-human claudin 18.2 antibody and application thereof | |
| JP7430924B2 (en) | competitive antigen binding protein | |
| JPH06510671A (en) | Production of chimeric antibodies - combinatorial approach | |
| Morino et al. | Antibody fusions with fluorescent proteins: a versatile reagent for profiling protein expression | |
| TW202227492A (en) | Anti-truncated mutant calr-cd3 bispecific antibody and pharmaceutical composition | |
| Visintin et al. | Intracellular antibodies for proteomics | |
| CN112442122B (en) | Blocking type PD-1 nano antibody and its coding sequence and use | |
| US20250269047A1 (en) | Anti-human b7-h3 antibody and application thereof | |
| US20050276800A1 (en) | Intrabodies | |
| US20050288492A1 (en) | Anti-activated RAS antibodies | |
| KR20220160670A (en) | Anti-PD-L1 and PD-L2 antibodies and their derivatives and uses | |
| Coomber et al. | Generation of anti-p53 Fab fragments from individuals with colorectal cancer using phage display | |
| CN110959015B (en) | Bispecific recombinant proteins | |
| Sepúlveda et al. | Binders based on dimerised immunoglobulin VH domains | |
| Mahgoub | Single chain fragment variables antibody binding to EGF receptor in the surface of MCF7 breast cancer cell line: application and production review | |
| Olsen et al. | Minimal structural elements of an inhibitory anti-ATF1/CREB single-chain antibody fragment (scFv41. 4) | |
| CN117986364A (en) | Nanoantibodies specifically binding to CD39 and uses thereof | |
| TW202413405A (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| Adams | Strategies for producing therapeutic antibodies in yeast |